SCHOFIELD, Wis., Feb. 23, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic™, announced today that it has received approval to run its direct response television commercials featuring its non-prescription migraine medication LipiGesic™ M on major cable networks.
In addition to its current lineup, PuraMed will now air its commercial on Arts & Entertainment Television Network (4 channels), Discovery Networks (12 channels), Viacom (16 channels), Turner (11 channels), Scripts (5 channels), Comcast (5 channels), Rainbow (2 channels), Fox Cable (4 channels), Lifetime (3 channels) and BET Networks (2 channels). PuraMed now has access to 10 networks and 64 stations across the U.S. The direct response television media mix has been customized for PuraMed's target audience of women, who suffer with migraines three times as much as men. Therefore, the LipiGesic™ M commercial will air more frequently on networks whose viewership is skewed toward women including Discovery Health, FIT TV, WE and Logo, to name a few.
Due to changes in recent guidelines affecting endorsement, testimonials and credit card charges implemented on Dec. 1, 2009 from the Federal Trade Commission (FTC) regarding direct response advertising, the approval process for the expansion of the LipiGesic™ M commercial to major cable networks took longer than expected. PuraMed's LipiGesic™ M Migraine commercial has been evaluated and approved, allowing for this expansion to additional major cable networks to take place.
"While we are increasing the number of networks where we are airing our direct response commercial, PuraMed is still currently in the test phase with its direct response media campaign. During this phase, the media spend is modest. We use this time to evaluate and optimize the commercials, the call center sales scripts, fulfillment, customer service and credit card processing," said PuraMed BioScience CEO Russell Mitchell. "We look at direct response advertising as the world's largest focus group. It's much easier to evaluate our price, promotion and packaging now than when the product is on the shelf at retail, so this is a critical step in ensuring our success in marketing and selling our products in the future. Once we reach our goals in test-market airing, our media spend is scheduled to increase substantially."
Mitchell continued, "Our goal with our direct response TV commercial is to create a self-funding media campaign to bring awareness to the LipiGesic™ brand prior to the retail launch. As our direct response campaign continues to expand, we will look to more aggressively pursue a social media campaign in conjunction with our TV ads. We look forward to then receiving substantial revenue to be generated from our e-commerce site and retail launch, with our product scheduled to begin seeing shelf presence in the third quarter 2010."
LipiGesic™ M may be purchased by calling 877-851-2190 or visiting http://www.mymigrainegone.com/">www.mymigrainegone.com or http://www.lipigesic.com/">www.lipigesic.com. The Company's two-minute direct response television commercial is available for viewing on these websites as well.
About the Company:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.